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Abstract
Background: Over the past decades, in spite of intensive search, no significant increase in the survival of patients with
glioblastoma has been obtained. The role of the blood-brain barrier (BBB) and especially the activity of efflux pumps belonging
to the ATP Binding Cassette (ABC) family may, in part, explain this defect.
Methods: The in-vitro activities of JAI-51 on cell proliferation were assessed by various experimental approaches in four human
and a murine glioblastoma cell lines. Using drug exclusion assays and flow-cytometry, potential inhibitory effects of JAI-51 on P-
gp and BCRP were evaluated in sensitive or resistant cell lines. JAI-51 activity on in-vitro microtubule polymerization was assessed
by tubulin polymerization assay and direct binding measurements by analytical ultracentrifugation. Finally, a model of C57BL/6
mice bearing subcutaneous GL26 glioblastoma xenografts was used to assess the activity of the title compound in vivo. An HPLC
method was designed to detect JAI-51 in the brain and other target organs of the treated animals, as well as in the tumours.
Results: In the four human and the murine glioblastoma cell lines tested, 10 μM JAI-51 inhibited proliferation and blocked cells
in the M phase of the cell cycle, via its activity as a microtubule depolymerising agent. This ligand binds to tubulin with an
association constant of 2 × 105 M-1, overlapping the colchicine binding site. JAI-51 also inhibited the activity of P-gp and BCRP,
without being a substrate of these efflux pumps. These in vitro studies were reinforced by our in vivo investigations of C57BL/6
mice bearing GL26 glioblastoma xenografts, in which JAI-51 induced a delay in tumour onset and a tumour growth inhibition,
following intraperitoneal administration of 96 mg/kg once a week. In accordance with these results, JAI-51 was detected by
HPLC in the tumours of the treated animals. Moreover, JAI-51 was detected in the brain, showing that the molecule is also able
to cross the BBB.
Conclusion: These in vitro and in vivo data suggest that JAI-51 could be a good candidate for a new treatment of tumours of the
CNS. Further investigations are in progress to associate the title compound chemotherapy to radiotherapy in a rat model.
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Background
Glioblastoma represents the most common type of pri-
mary tumours of the central nervous system (CNS) [1],
and has a poor prognosis (less than 12 months), requiring
a multidisciplinary approach, including surgery, radio-
therapy and chemotherapy [2]. The use of common anti-
cancer drugs is hampered by the presence of the blood-
brain barrier (BBB), causing poor distribution of these
agents. This restrictive action of the BBB has been linked
to the presence on the brain endothelial cells of drug
efflux transport systems, especially transporters belonging
to the ATP Binding Cassette (ABC) family [3,4], out of
which two have been shown to have a functional impor-
tance in vivo on the BBB: the P-glycoprotein (P-gp/ABCB1)
and the Breast Cancer Resistance Protein (BCRP/ABCG2)
[5-8].
One way of efficiently treating glioblastoma is to identify
bifunctional molecules able not only to block glioblast-
oma cells proliferation, but also to cross the BBB without
being effluxed by ABC proteins. In searching for such mol-
ecules, we targeted the naturally occurring flavonoids and
their derivatives [9]. We have already described the poten-
tial of flavonoid derivatives as antimitotics and as multid-
rug reversers [10-12]. In the present report, we describe
the biological activities of a new derivative named JAI-51.
This compound was identified by screening of a large
series of chalcones and was optimized to obtain the best
biological activity.
Methods
Chemical synthesis of JAI-51
The pharmacophore of the title compound was identified
through a screening process. The optimization phase,
which deals with identification of the optimal substitut-
eds, led to the identification of JAI-51. The access to the
target compound was achieved in one step starting from
2',4',6'-trimethoxyacetophenone (Figure 1). The latter was
condensed with 1-methylindolyl-3-carboxaldehyde in the
presence of KOH in a mixture of H2O:MeOH [12].
In vitro studies
Culture of glioblastoma cell lines
Human glioblastoma derived cell lines U118, U138,
U373 and LN229 were generously provided by Pr F.
Berger (INSERM U318). These four cell lines as well as
HCT116S and R, K562S and R, and the mouse glioma cell
line GL26, were maintained in RPMI 1640 (U118, U138,
U373, LN229) or DMEM (GL26) medium with 10% (v/v)
inactivated fetal calf serum (FCS) (Gibco BRL, Eragny,
France), antibiotics (penicillin 100 IU.ml-1 and strepto-
mycin 100 μg.ml-1), and L glutamine (2 mM) (Roche,
Meylan, France) at 37°C in a humidified atmosphere with
5% CO2. In induced cultures, cells were seeded at 0.3 ×
106 cells ml-1 for 24 h before the addition of various doses
of JAI-51 (1 μM to 10 μM) or DMSO (vehicle/0.1%) for
various times (24 to 48 hours). At the indicated time, cells
were trypsinized then non-adherent and adherent
trypsinized cells were used for the determination of cell
proliferation, cell cycle and apoptosis.
Proliferation, apoptosis and cell cycle analyses
The number of total and viable cells was determined using
Trypan blue (0.4%) exclusion in triplicate and the mean
value determined was then confirmed by MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bro-
mide) assay, as described by the manufacturer (Sigma
Aldrich, l'Isle d'Abeau, France) by using 1 to 10 μM JAI-51
for 24 and 48 hours. Cell DNA content was analyzed
using the CycleTestTM PLUS/DNA reagent kit (BD Sci-
ences, San Jose, CA). Data were collected and analyzed on
a FACSCalibur flow-cytometer (Becton Dickinson, La
Jolla, CA) using CELLQUEST PROTM software (BD Sci-
ences, Le Pont de Claix France). Apoptosis was confirmed
using the Annexin V-FITC/PI method (Vybrant™ Apopto-
sis Assay kit, Molecular Probes, Eugene, OR) by flow-
cytometry. The role of Caspase-3 in the apoptotic process
Chemical synthesis of JAI-51 Figure 1
Chemical synthesis of JAI-51. See methods section for details.BMC Cancer 2009, 9:242 http://www.biomedcentral.com/1471-2407/9/242
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was determined by the Caspase-3 Fluorimetric Assay
(R&D Systems, Mineapolis, MN) as described by the man-
ufacturer.
Determination of the mitotic index
At 24 hours induction time, tumour cells were
trypsinized, cytocentrifuged (Cytospin, Shandon, Pitts-
burgh, PA) and stained using the Papanicolaou proce-
dure. The mitotic index and the number of polynucleated
cells were then determined on 300 cells with conventional
morphology analysis using a Zeiss microscope (Oberko-
chen, Germany).
In-vitro evaluation of JAI-51 on BCRP and P-gp activities
The accumulation studies of mitoxantrone (BCRP sub-
strate) and daunorubicin (P-gp substrate) were performed
using wild type (sensitive) HCT116 cell line (HCT116S)
which does not express BCRP, and the BCRP-transfected
resistant form HCT116R, and on wild-type (sensitive)
K562S or P-gp expressing (resistant) K562R cell lines
[10,11]. Cells grown in RPMI 1640 medium with 10%
FCS were trypsinized (HCT116), washed twice then re-
suspended in RPMI 1640 medium with 10% FCS to
obtain a density of 106 cells/ml. JAI-51 at various concen-
trations (10-7 to 10-5 M) or the BCRP and P-gp inhibitor
cyclosporine A (1 μM final concentration) was added to 1
ml of cells and incubated for 15 min at 37°C, followed by
addition of mitoxantrone (final concentration 3 μM) or
daunorubicin (final concentration 1 μM). After 30 min of
incubation at 37°C, 4 ml of ice-cold PBS were added to
stop drug accumulation and fluorescence was quantified
by flow-cytometry. Mitoxantrone and daunorubicin accu-
mulation studies were also performed on the glioblast-
oma cell lines used in our study, in order to test for the
presence of functional P-gp and/or BCRP efflux pumps on
these cell lines.
Evaluation of JAI-51 as a potential substrate of P-gp and/or BCRP
HCT116/S and R, K562/S and R exponentially growing
cells were incubated for 24 hours in the presence of
DMSO (vehicle/0.1%) or JAI-51 (10 μM). Cell cycle anal-
yses were done as described above.
In vitro tubulin polymerization assay and direct binding measurement
Tubulin was purified from soluble lamb brain homoge-
nate by ammonium sulfate fractionation and ion
exchange chromatography according to the published
method [13-17].
Microtubule assembly was assayed in 20 mM sodium
phosphate (NaPi), 10 mM MgCl2, 1 mM EGTA, 3.4 M
glycerol, and 0.1 mM GTP, pH = 6.5, in the presence of
various concentrations of JAI-51 (0–15 μM). The polym-
erization reaction (15 μM tubulin) was started by increas-
ing the temperature to 37°C and the mass of polymer
formed was monitored in thermostated cuvettes by meas-
uring turbidity at 350 nm in a Beckman DU 7400 spectro-
photometer [13]. The concentration of JAI-51 (stock
solution in DMSO) was measured spectrophotometrically
with an extinction coefficient ε392 nm = 27,000 M-1.cm-1.
The sedimentation of tubulin and tubulin-colchicine was
analyzed, without and with various concentrations of JAI-
51 (2.5–36 μM) in PG buffer (NaPi 20 mM, GTP 10-4 M,
pH = 7.0). The experiments were carried out at 40,000
rpm and 20°C in a Beckman Optima XL-A analytical
ultracentrifuge equipped with absorbance optics, using an
eight holes An50Ti rotor and 1.2 cm Epon double-sector
centrepieces. Data were acquired in continuous mode at
392 nm, the maximum wavelength of JAI-51 (ε392 nm =
18,100 M-1 cm-1, solution in aqueous neutral buffer).
Apparent sedimentation coefficients were determined by
the sedimentation coefficient distribution C(S) generated
by SEDFIT program [18]. These analyses allowed us to
quantify the bound ligand concentration by measuring
the area under the tubulin sedimenting peak (5.4S) and
the free concentration by measurement of the baseline
(which represents the ligand that does not sediment, i.e,
the free ligand). For various concentrations of JAI-51,
bound ligand divided by total tubulin (B) was plotted ver-
sus free ligand (L) concentrations and the apparent asso-
ciation constant, K and the stoichiometry (n) were
determined using the following equation:
In vivo studies
Animals
C57BL/6 mice 5 to 6 weeks old with a weight of 20 ± 2 g
were obtained from Elevage Janvier (Le Genest St Isle,
France) and kept under pathogen-free conditions in the
animal facility of the University Joseph Fourier. All animal
experiments were approved by the Animal Experiment
Committee of the University and were performed in
accordance with institutional and national guidelines.
Treatment of subcutaneously implanted GL26 tumors
GL26 cells (1 × 105 cells in 100 μl PBS) were implanted
subcutaneously in the left flank of each mouse. JAI-51
treatment was delivered intraperitonealy (ip) in 100 μl
PBS. One group received only the vehicle (control), one
group was treated three times a week with 32 mg/kg JAI-
51 (schedule N°1) and one group was treated once a week
with 96 mg/kg JAI-51 (schedule N°2). The first injection
was done 48 h after the tumour challenge. The mice were
inspected each day to detect the presence of a palpable
tumour. The tumour size was then assessed by caliper
measurement 2, 4, 7 and 11 days after the apparition of
the tumour and the mice were sacrificed when the tumour
B
bound ligand
tubulin
n K L
1KL
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[]
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size reached 10 millimetres. The day of GL26 cells implan-
tation was designated as day 0.
Detection of JAI-51 in mice after intraperitoneal administration
A sensitive and reliable high performance liquid chroma-
tography method (HPLC) with UV detection, using a
solid-phase extraction (SPE) was established for detection
of JAI-51 in brain, liver, kidney and tumours of mice.
Saline perfusion (wash-out) was used to reduce intravas-
cular contamination before collecting organs that were
immediately frozen at -80°C. After thawing, organs were
grinded, diluted with water, applied to a solid-phase
extraction C18 cartridge and extracted by acetonitrile. The
samples were analyzed by HPLC using UV detection at
386 nm. The limit of detection (LOD with S/N = 3) for
JAI-51 was 3.85 × 10-7 M and the linearity of the calibra-
tion curves was prepared by fitting absorbance vs. amount
of JAI-51 standards between 3.85 × 10-7 M and 20 × 10-7
M (measured 3 times). As a control, a known concentra-
tion of JAI-51 was analyzed in the same experimental con-
ditions as the samples to be sure that the peak detected
corresponded to JAI-51. The detection of the unmetabo-
lized compound was performed on brain, liver and kid-
ney of three untreated mice and on three mice treated with
JAI-51 (schedules 1 and 2) two days after the injection. On
tumours, the detection was done an hour and a half after
the injection, on three untreated mice and on three mice
treated with schedule 2, as this schedule was the one
showing a significant decrease in the mean tumour vol-
ume compared to the control mice.
Data analysis
Data are expressed as the mean ± SD of 2 (in vivo studies)
or at least 3 (in vitro studies) experiments. For statistical
analysis of in vitro data, one-way ANOVA was performed
to determine differences among all groups (P < 0.05), and
the Bonferroni/Dunn posttest was performed to deter-
mine the significance of the differences between pairs of
groups. P < 0.05 was considered significant. The statistical
tests were performed on StatView software (version 5.0,
SAS Institute, Inc., Cary, NC). The in vivo data were ana-
lyzed with GraphPad Prism (version 5, La Jolla, CA) and
following one-way ANOVA analysis, Dunn's Multiple
Comparison Test was used to determine the significance
of the differences between each of the two treatment
schedules versus the control group.
Results
Effects of JAI-51 on glioblastoma tumor cell lines
Using four human glioblastoma cell lines (U118, U138,
U373 and LN229) and one mouse glioblastoma cell line
(GL26), JAI-51 was tested at concentrations varying from
1 to 10 μM and for various time points. Four parameters
were subsequently analyzed: cell proliferation, cell cycle,
apoptosis and mitotic index.
The inhibition of cell proliferation as determined by the
MTT test was time- and dose-dependent, with the concen-
trations of 5 μM and 10 μM of JAI-51 modulating the
most the proliferation of the five cell lines (Figure 2/A).
Indeed, after 24 h induction time with 10 μM JAI-51, the
decrease in proliferation was statistically significant for all
the cell lines tested compared to the untreated cells (P <
0.05 treated versus control), and after 48 h induction
time, this decrease in proliferation was also significant
with 5 μM JAI-51 for all the cell lines tested (P < 0.05
treated versus control).
At 24 hours induction time with 10 μM JAI-51, cell cycle
distribution analysis showed a dramatic increase in the
percentage of cells in the G2/M phase together with a
decrease in G0/G1 and S populations (Figure 2/B and
Table 1). Papanicolaou staining showed that the mitotic
index (MI) increased in all the cell lines tested, suggesting
an arrest in the M phase of the cell cycle (Figure 2/Cleft
panel and D). Moreover, at 48 hours, the percentage of
cells in the sub-G0/G1 phase (hypodiploid cells) dramat-
ically increased, suggesting an apoptotic process (data not
shown). To confirm this hypothesis, cells were treated
with JAI-51 (10 μM for 48 hours) and the cell death proc-
ess was investigated using the Annexin V-FITC/PI method
and the Caspase-3 Fluorimetric Assay. The percentage of
apoptotic cells and of hypodiploid cells increased after
JAI-51 treatment in the five glioblastoma cell lines (Figure
2/Cright panel). Apart from U138 cell line, the apoptotic
process induced by 10 μM JAI-51 was Caspase-3 depend-
ent (Table 2).
Effect of JAI-51 on MDR cancer cell lines
In K562/R and HCT116/R cell lines, 10 μM JAI-51
restored the intracellular accumulation of daunorubicine
(Figure 3/A) or mitoxantrone (Figure 3/B) with the same
rate as the P-gp and BCRP-inhibitor cyclosporine A, show-
ing that JAI-51 is also an inhibitor of these pumps. Figure
3/C shows that 10 μM JAI-51 was able to induce a cell
cycle arrest in the G2/M phase, and an increase in both the
percentage of apoptotic cells and the mitotic index (data
not shown) of K562/R and S and HCT116/R and S cells.
As the same effect of JAI-51 on the cell cycle was observed
on all the cell lines tested, irrespective of the presence or
not of an efflux pump, this shows that JAI-51 is not
extruded by (i.e. is not a substrate of) P-gp (K562R cells)
nor of BCRP (HCT116R cells). Taken together, these
results show that JAI-51 is an inhibitor of P-gp and BCRP
but is not a substrate of these pumps.
Effect on tubulin polymerization and interaction tubulin-
JAI-51
Figure 4/A shows the effects of JAI-51 on the turbidimetry
time course of microtubule assembly from pure tubulin.
A clear inhibition was noted and the rate of assembly, asBMC Cancer 2009, 9:242 http://www.biomedcentral.com/1471-2407/9/242
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well as the final amount of microtubules, was lower in the
presence of JAI-51 (curves 2–6) than in the control (curve
1). Figure 4/B shows that the turbidity generated by the
self-assembly of 15 μM tubulin was reduced by half with
11.25 μM JAI-51. Figure 4/C shows that the extent of inhi-
bition by JAI-51 increased monotonically with the mole
ratio of the total ligand to total tubulin in the solution
(R). In this figure, 50% inhibition occurred with 0.75 mol
of JAI-51 per mol of tubulin, indicating a substoichiomet-
ric mode of inhibition.
To understand the mechanism of this inhibition, the
interaction of JAI-51 with tubulin was studied by analyti-
cal ultracentrifugation. In the presence of JAI-51, the sed-
imentation coefficient of tubulin remained unchanged
(5.4 S). Bound ligand concentration divided by total pro-
tein concentration (bound fraction, B) was plotted versus
free ligand concentration (L) (Figure 4/D) and analyzed as
described in the Methods section. JAI-51 displayed a stoi-
chiometry of n = 1.3 ± 0.6 with an apparent association
constant of (1.9 ± 0.6) × 105 M-1, similar to that of MTC
(2methoxy-5-(2', 3', 4'-trimethoxyphenyl)-topone), a
bifunctional analog of colchicine [13], with a structure
closely related to that of MDL 27048 [trans-1-(2,5-
dimethoxyphenyl)-3-[4-(dimethylamino)phenyl]-2-
methyl-2-propen-1-one]. As these two latter compounds
bind to the colchicine site, we examined the interaction of
JAI-51 with tubulin-colchicine complexes by analytical
ultracentrifugation. A stoichiometry of n = 0.40 ± 0.07
was measured, showing that the binding of JAI-51 to
tubulin-colchicine complexes was essentially inhibited.
In vivo effects in mice
In our murine xenograft model, the first tumours were
observed on day 20 and the apparition of the tumours was
monitored on days 22, 24, 27 and 31. Data in Figure 5/A
show that the tumour onset and progression were delayed
in the group of mice treated with schedule 1, and even
more dramatically so in the group treated with schedule 2.
Indeed, with schedule 2 (96 mg/kg JAI-51 once a week),
the first tumours were detected on day 24 and the percent-
age of mice with a detectable tumour remained
unchanged until the end of the experiment. In the group
treated with schedule 1 (32 mg/kg three times a week), the
number of mice with a detectable tumour and tumour
progression was decreased compared to the control group,
but to a lesser extent. Moreover, the mean tumour vol-
umes were significantly lower in the group treated with
schedule 2, throughout the length of the experiment (Fig-
ure 5/B) compared to the control group (P  < 0.05)
whereas there was no significant difference between the
group treated with schedule 1 and the controls.
JAI-51 was detected by HPLC in the tumours of mice
treated with schedule 2 an hour and a half before sacrifice
(Figure 5/C, upper panel). As a control, a known concen-
tration of JAI-51 was analyzed in the same experimental
conditions as the samples to be sure that the peak detected
Effects of JAI-51 on a panel of glioblastoma cell lines Figure 2 (see previous page)
Effects of JAI-51 on a panel of glioblastoma cell lines. U118, U138, U373, LN229 cells were cultured for 24 h before the 
addition of JAI-51 (1 to 10 μM). Cells were used for either cell proliferation tests using MTT at the indicated times (A) or for 
cell cycle analysis at 24 h (B). (A) After 24 h induction time with 10 μM JAI-51, the decrease in proliferation was statistically 
significant for all the cell lines tested compared to the untreated cells (P < 0.05 treated versus control), and after 48 h induction 
time, this decrease in proliferation was also significant with 5 μM JAI-51 for all the cell lines tested (P < 0.05 treated versus con-
trol). The results are expressed as the mean ± SD from 3 different experiments. Mitotic index (M.I.) (C, left panel) was 
determined at 24 h on slide after Papanicolaou staining, and apoptosis (C, right panel) was determined at 48 h using the 
Annexin V-FITC/PI method (* P < 0.05 treated versus control). (D) Photomicrographs of control LN229 and GL26 cells and 
cells treated with 10 μM JAI-51 for 24 h (LN229+JAI-51, GL26+JAI-51). Treated LN229 and GL26 cells displayed polylobated 
nuclei and most of the mitotic figures showed numerous abnormalities (complex spindle with several poles). (Magnification × 
600).
Table 1: Percentage of cells in the cell cycle phases after 24 hours incubation with 10 μM JAI-51
Cell cycle phase U118C U118T U138C U138T U373C U373T LN229C LN229T GL26C GL26T
G0/G1 60 ± 9 30 ± 5 * 54 ± 6 32 ± 6 * 54 ± 4 21 ± 3 * 53 ± 5 12 ± 4 * 55 ± 8 30 ± 5 *
S 18 ± 2 15 ± 3 10 ± 2 9 ± 2 20 ± 2 15 ± 2 18 ± 3 19 ± 4 22 ± 3 10 ± 3
G2/M 22 ± 3 55 ± 7 * 34 ± 7 58 ± 6 * 26 ± 3 64 ± 6 * 28 ± 3 68 ± 6 * 23 ± 4 60 ± 8 *
Glioblastoma cells were cultured for 24 hours without (C) or with 10 μM JAI-51 (T) before being stained with propidium iodide. DNA content was 
analyzed by flow-cytometry and the percentage of cells in each phase of the cell cycle was obtained by using Modfit program. Numbers ± SD 
indicate the percentage of cells and are the mean of 3 to 5 experiments. * P < 0.05 (treated versus control).BMC Cancer 2009, 9:242 http://www.biomedcentral.com/1471-2407/9/242
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corresponded to JAI-51 (Figure 5/C, lower panel and Fig-
ure 5/D, lower panel). The chromatograms showed a
high intensity of JAI-51 in the tumours, ten times higher
than the limit of detection which was 3.85 10-7 M by this
method (Figure 5/D, lower panel). A second peak was
also detected, probably corresponding to a metabolite of
the title compound.
JAI-51 was also detected by HPLC in the brain of
xenografted mice treated following schedule 1 (Figure 5/
D, upper panel). The same results were obtained in the
brains of mice treated with schedule 2 (data not shown).
JAI-51 was also detected in the liver and kidney of treated
mice (data not shown); the yield of extraction (see the
Material and Methods section for details) of the organs
from treated mice, were 92 ± 4% in the brain and 89 ± 2
and 86 ± 3 in the kidney and liver respectively.
Discussion
Flavonoid and chalcone derivatives possess various prop-
erties such as inhibition of cell proliferation, associated or
not to an inhibition of tubulin polymerization [19], or
modulation of ABC pumps [10,11,20]. Some of these
molecules cross the BBB [9] and induce apoptosis in can-
cer cells [21], but to date no molecule displaying all these
activities has been described. In this context, we report the
in-vitro and in-vivo effects of a new chalcone derivative,
named JAI-51.
In vitro, JAI-51 reduces the proliferation of glioblastoma
cell lines from human and mouse origins and induces
Table 2: Effect of JAI-51 on the apoptotic process in the glioblastoma cell lines.
Cell line U118 U138 U373 LN229 GL26
Caspase-3 activity (A.U.) 13 ± 3* 6 ± 2 39 ± 3* 120 ± 25* ND
Hypodiploid cells (%) 26 ± 10* 17 ± 1* 20 ± 2* 30 ± 5* 25 ± 5*
Apoptotic+necrotic cells (%) 21 ± 5* 20 ± 3* 34 ± 2* 31 ± 2* 25 ± 8*
Glioblastoma cells were cultured for 24 h before the addition of JAI-51 (10 μM) for 48 h. Caspase-3 activity, the percentage of cells with a DNA 
content <2 N (hypodiploid cells) and the percentage of apoptotic and necrotic cells were assessed. Results are the mean ± SD of 3 experiments. In 
the control cultures (not treated with JAI-51), Caspase activity was 4 ± 1 A.U. and the percentage of apoptotic cells was < 3% in all the cell lines. 
A.U.: arbitrary units; %: percentage of cells. * P < 0.05 (treated versus control).
Inhibition of P-gp and BCRP Figure 3
Inhibition of P-gp and BCRP. (A) Effects of JAI-51 on wild-type (S, sensitive) and on P-gp overexpressing (R, resistant) 
K562 cell lines, with or without daunorubicin (P-gP substrate) and/or cyclosporin (P-gP inhibitor). (B) Effects of JAI-51 on wild-
type (S, sensitive) and on BCRP overexpressing (R, resistant) HCT116 cell lines, with or without mitoxantrone (BCRP sub-
strate) and/or cyclosporin (BCRP inhibitor). (C) Percentage of cells in the G2/M phase of the cell cycle after JAI-51 treatment. 
K562/S and K562/R (A), HCT1162/S and HCT116/R (B) cells were treated with DMSO (vehicle/0.1%) (control) or JAI-51 (10 
μM) and analyzed as described in the Methods section. Drug accumulation results are expressed in mean fluorescence intensity 
(M.F.I.) in arbitrary units. The results are expressed as the mean ± SD from 3 different experiments. * P < 0.05 cyclosporin or 
JAI-51-treated resistant cells versus their respective control. (C) To test whether JAI-51 was a substrate of P-gp and/or BCRP, 
multidrug resistant cells and their respective parental cell lines (HCT116/R, HCT116/S, K562/R and K562/S) were incubated in 
the presence of JAI-51 (10 μM). Phases of the cell cycle were analyzed at 24 h as described in Figure 1B. G2/M is expressed in 
% of cells. The results are expressed as the mean ± SD from 3 different experiments. * P < 0.05 JAI-51-treated versus control.BMC Cancer 2009, 9:242 http://www.biomedcentral.com/1471-2407/9/242
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Tubulin assembly in the presence of JAI-51 and binding of JAI-51 on tubulin Figure 4
Tubulin assembly in the presence of JAI-51 and binding of JAI-51 on tubulin. (A) Effect of various concentrations of 
JAI-51 (1: 0 μM; 2: 5 μM; 3: 7.5 μM; 4: 10 μM; 5: 12.5 μM; 6: 15 μM) on 15 μM tubulin, in polymerization buffer. Assembly was 
started by warming the samples at 37°C (arrow). (B) Represents the fraction of the reduction of the plateau absorbance values 
(inhibition) as a function of total JAI-51 concentrations. (C) Percentage of polymerization inhibition as a function of the mole 
ratio of the total JAI-51 to total tubulin in the solution (R). (D) Study of the binding of JAI-51 on tubulin by analytical ultracen-
trifugation. Circles are the experimental points and the solid line is the fit obtained as described in the Methods section. In 
these experiments one binding site was found (n = 1.3 ± 0.6) with an affinity constant of (1.9 ± 0.6) 105 M-1.BMC Cancer 2009, 9:242 http://www.biomedcentral.com/1471-2407/9/242
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apoptosis, in some cases through a Caspase-3 dependent
pathway, depending on the cell line studied. For U138 cell
line, a Caspase-independent apoptosis process could be
involved, as reviewed by Tait and Green [22]. This phe-
nomenon can occur during mitosis and has been
described to be a mechanism for protecting cells from an
endoreplicative process [23]. It has also been demon-
strated that flavonoids can induce apoptosis by both Cas-
pase-mediated or Caspase-independent processes [24].
Our compound acts in a dose- or a time-dependent man-
ner: low doses or short induction times induce a cytostatic
effect whereas higher concentrations or higher induction
times induce a cytolytic effect. The differences in the reac-
tions of the various cell lines on JAI-51 incubation were
not related to the presence of P-gp or BCRP, as a func-
tional assay showed no accumulation of daunorubicin (P-
gp substrate) or mitoxantrone (BCRP substrate) in these
cell lines (data not shown). Hence, the differences in the
cytostatic effects of JAI-51 on the cell lines tested were
probably due to differences in the doubling times of these
cell lines. Cytological analyses showed that JAI-51 blocks
cell cycle in metaphase, probably by modulating microtu-
bule stability. This destabilizing effect was characterized
in a cell-free system and the substoichiometric concentra-
tions of JAI-51 in relation with the tubulin concentration
were sufficient to block tubulin polymerization in a way
similar to vincaalkaloids or colchicine. JAI-51 is able to
compete with colchicine for the same binding site that
induces inhibition of tubulin polymerization. Tubulin
targeting agents are usually classified in two groups,
In-vivo effects of JAI-51 on mice bearing subcutaneous GL26 xenografts Figure 5
In-vivo effects of JAI-51 on mice bearing subcutaneous GL26 xenografts. (A) Tumour onset and progression and (B) 
Mean tumour volumes, in JAI-51 treated GL26 xenografted mice. Control: untreated mice (n = 16), schedule 1: mice treated 3 
times a week with 32 mg/kg JAI-51 (n = 10); schedule 2: mice treated once a week with 96 mg/kg JAI-51 (n = 6). Results are 
from one representative experiment out of two. For (B) statistical analysis using Dunn's Multiple Comparison Test following 
one-way ANOVA showed that the mean tumour volumes were significantly lower in the group treated with schedule 2 com-
pared to the control group throughout the length of the experiment (P < 0.05). (C, upper panel) chromatogram of JAI-51 in 
the tumours of mice treated with schedule 2, an hour and a half before sacrifice. (D, upper panel) chromatogram of brain 
homogenates from JAI-51 treated mice. As controls, known amounts of JAI-51 were analyzed in the same experimental condi-
tions (C and D, lower panels).BMC Cancer 2009, 9:242 http://www.biomedcentral.com/1471-2407/9/242
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according to their effects: microtubule stabilizers such as
taxol and epothilone and microtubule destabilizers
including vincaalkaloids and colchicine. In the same way
as microtubule destabilizers [25-27], JAI-51 is able to dis-
rupt the formation of microtubules, leading to pro-
nounced G2/M cell cycle arrest and apoptosis. Classically,
one of the limiting phenomena for the use of common
microtubule destabilizers is drug resistance mediated by
P-gp or BCRP. However, in the present study, no differen-
tial cytotoxic activities (through cell cycle analysis) were
observed between sensitive and resistant cell lines overex-
pressing P-gp or BCRP, suggesting that JAI-51 is not a sub-
strate for these efflux pumps, in drastic contrast to
vinblastine and paclitaxel [28]. In accordance with our
results, Liu et al. [20] reported a chalcone which can
inhibit both P-gp and BCRP and whose structure is similar
to that of JAI-51, which was developed from a basic chal-
cone with a meta dimethoxy motif on ring A, an impor-
tant feature for activity, as proposed by Seelig and
Landwojtowicz [29]. Moreover, the active concentrations
used in the study of Liu et al. [20] are closely related to
those obtained in our experiments. However the authors
didn't investigate the biological activities of their com-
pound other that P-gp and BCRP inhibition.
In vivo, in a model of sc GL26 xenografted C57BL/6 mice,
our compound induced a delay in tumour onset and a
tumour growth inhibition at 96 mg/kg once a week
(schedule 2). In accordance with these results, HPLC anal-
ysis of tumours from mice treated with schedule 2 showed
that JAI-51 reached concentrations similar to those induc-
ing a cytostatic effect in our in vitro studies.
JAI-51 was also detected by HPLC in the liver, kidney and
brain of treated mice. As these organs express a high level
of ABC pumps, these results reinforce those obtained in
vitro showing that our compound is a modulator without
being a substrate of these ABC pumps. Moreover, as JAI-
51 was detected in the brain of the treated mice, this
shows that our compound is able to cross the BBB. In
addition, no toxicity in terms of blood cell counts, body
weight or behaviour was observed in the treated animals
(data not shown).
Conclusion
In view of our results, when compared to other anticancer
agents, our compound possesses a number of interesting
properties. Alone or associated to recent progress made in
the treatment of tumours of the CNS including either new
methods for direct delivery of chemotherapy [30] or novel
approaches for transporting drugs into the CNS [31], JAI-
51 could be a promising new drug. In glioblastoma
patients, JAI-51 could also be efficient on the malignant
cells infiltrating the surrounding tumour and which are
located under areas with an intact BBB [32].
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